9,920 Shares in Axon Enterprise, Inc $AXON Acquired by Estate Counselors LLC

Estate Counselors LLC acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the first quarter, according to its most recent filing with the SEC. The firm acquired 9,920 shares of the biotechnology company’s stock, valued at approximately $5,217,000. Axon Enterprise comprises approximately 0.5% of Estate Counselors LLC’s holdings, making the stock its 23rd largest holding.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company’s stock valued at $402,210,000 after acquiring an additional 763,431 shares during the last quarter. Jennison Associates LLC lifted its position in Axon Enterprise by 23,203.7% during the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after purchasing an additional 611,418 shares during the period. Nuveen LLC bought a new position in shares of Axon Enterprise in the 1st quarter valued at about $264,796,000. Westfield Capital Management Co. LP grew its position in shares of Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after buying an additional 212,931 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Axon Enterprise by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after buying an additional 185,571 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $760.89 on Thursday. The firm has a market cap of $59.73 billion, a PE ratio of 187.87, a PEG ratio of 27.83 and a beta of 1.36. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 1-year low of $346.71 and a 1-year high of $885.91. The company has a fifty day moving average price of $773.57 and a 200 day moving average price of $672.61.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. The company had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company’s quarterly revenue was up 32.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. Research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $831.29, for a total transaction of $8,312,900.00. Following the completion of the transaction, the chief executive officer owned 3,053,982 shares of the company’s stock, valued at $2,538,744,696.78. This represents a 0.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Jennifer H. Mak sold 75 shares of the firm’s stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $771.81, for a total transaction of $57,885.75. Following the transaction, the chief accounting officer directly owned 15,240 shares of the company’s stock, valued at $11,762,384.40. This represents a 0.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,790 shares of company stock worth $33,654,451. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on AXON shares. Wolfe Research initiated coverage on shares of Axon Enterprise in a report on Monday, July 7th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. increased their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a report on Thursday, July 17th. JMP Securities boosted their price target on shares of Axon Enterprise from $725.00 to $825.00 and gave the company a “market outperform” rating in a report on Tuesday, July 22nd. The Goldman Sachs Group upped their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a research report on Wednesday, May 14th. Finally, Needham & Company LLC set a $870.00 price objective on Axon Enterprise and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average price target of $837.69.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.